Comment on: Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice SIR, I was pleased to read the recent article on the short-term value of tocilizumab (TCZ) in decreasing the daily oral prednisone dose (DOPD) in RA patients in a real-life setting [1] . The proportion of RA patients receiving TCZ with a DOPD of 45 mg increased from 32% at baseline to 54% after 24 weeks and 12% were off prednisone at 24 weeks [1] . However, I have some concerns about the study design, the reporting and interpretation of the results.
. Actually, Table 2 of our article [2] does report the results of intention-to-treat analysis with last observation carried forward. The numbers in brackets provided below the mean values or percentages correspond to the number of patients really followed during the considered study period, but data from patients lost to follow-up were included in the analyses. These numbers were added in order to provide more precision, but might have compromised the general understanding of the table, so we apologize for that. The results of the completer analyses are provided in Table 1 of this letter. The study [2] evaluates what happens in real life. It is not a double-blind randomized study, but an open, observational study, with limitations inherent in such work. We believe that a dropout rate of 19% is satisfactory regarding this particular design. In addition, in order to minimize the limitation due to dropouts, we performed both intention-to-treat and completer analyses, which provided similar results.
We agree that physician preference has probably impacted the results. However, we do not consider that as a bias since observational studies also evaluate physicians' preferences and habits. The present study [2] is of particular interest on that point, since it suggests that in patients treated with high daily doses of CS, the physician's main objective might be to reduce this dose rather than to obtain low disease activity or remission.
Finally, we agree that data on the IA use of CSs would have been of interest. Unfortunately, the retrospective design of the study [2] did not allow us to obtain such data, which (unfortunately) are not always provided in articles presenting results of double-randomized trials. Statistical analyses used analysis of variance with repeated measures, thus used only data from the patients followed throughout the 6 months of the study. DAS28-ESR: 28-joint DAS with ESR; EULAR: European League Against Rheumatism; VAS: visual analogue score.
